{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T18:36:55Z","timestamp":1783535815792,"version":"3.55.0"},"reference-count":38,"publisher":"Walter de Gruyter GmbH","issue":"6","funder":[{"name":"China National Key Projects for Infectious Disease","award":["2018ZX10302205-003"],"award-info":[{"award-number":["2018ZX10302205-003"]}]},{"name":"Shanghai Science and Technology Commission","award":["17411960500"],"award-info":[{"award-number":["17411960500"]}]},{"name":"Shanghai Science and Technology Commission","award":["17JC1404500"],"award-info":[{"award-number":["17JC1404500"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2020-1588_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Liver cirrhosis (LC) is the end-stage of fibrosis in chronic liver diseases, non-invasive early detection of liver fibrosis (LF) is particularly essential for therapeutic decision. Aberrant glycosylation of glycoproteins has been demonstrated to be closely related to liver abnormalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-1588_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was designed to enroll a total of 1,565 participants with LC\/LF, chronic hepatitis virus (CHB) and healthy controls. Fibrosis was confirmed by liver biopsy. Using capillary electrophoresis N-glycan fingerprint (NGFP) analysis, we developed a nomogram algorithm (FIB-G) to discriminate LC from non-cirrhotic subjects.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-1588_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The FIB-G demonstrated good diagnostic performances in identifying LC with the area under the curve (AUC) 0.895 (95%CI: 0.857\u20130.915). Furthermore, the diagnostic efficiencies of FIB-G were superior to that of log (P2\/P8), procollagen III N-terminal (PIIINP), type IV collage (IV-C), laminin (LN), hyaluronic acid (HA), aspartate transaminase to platelets ratio index (APRI), and FIB-4 when detecting significant fibrosis (S0\u20131 vs. S2\u20134, AUC: 0.787, 95%CI: 0.701\u20130.873), severe fibrosis (S0\u20132 vs. S3\u20134, AUC: 0.844, 95%CI: 0.763\u20130.924), and LC (S0\u20133 vs. S4, AUC: 0.773, 95%CI: 0.667\u20130.880). Besides, changes of FIB-G were associated well with the regression of fibrosis and liver function Child\u2013Pugh classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2020-1588_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>FIB-G is an accurate multivariant N-glycomic algorithm for LC prediction and fibrosis progression\/regression monitoring. The high throughput feasible NGFP using only 2\u00a0\u03bcL of serum could help physicians make the more precise non-invasive staging of LF or cirrhosis and reduce the need for invasive liver biopsy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2020-1588","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T06:39:20Z","timestamp":1611383960000},"page":"1087-1097","source":"Crossref","is-referenced-by-count":3,"title":["Serum N-glycan fingerprint nomogram predicts liver fibrosis: a multicenter study"],"prefix":"10.1515","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-6262","authenticated-orcid":false,"given":"Chenjun","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Mengchao Hepatobiliary Hospital of Fujian Medical University , Fuzhou , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Changzheng Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Mengchao Hepatobiliary Hospital of Fujian Medical University , Fuzhou , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , The First Affiliated Hospital of Kunming Medical University , Kunming , Yunnan , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"},{"name":"Department of Emergency Medicine, Jinling Hospital , Medical School of Nanjing University , Nanjing , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Data Analysis , Wonders Information Co. LTD. , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine , Shanghai Eastern Hepatobiliary Surgery Hospital , Shanghai , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"2021082201593411282_j_cclm-2020-1588_ref_001","doi-asserted-by":"crossref","unstructured":"El-Serag, HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264\u201373.e1. https:\/\/doi.org\/10.1053\/j.gastro.2011.12.061.","DOI":"10.1053\/j.gastro.2011.12.061"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_002","doi-asserted-by":"crossref","unstructured":"Gassmann, P, Spieker, T, Haier, J, Schmidt, F, Mardin, WA, Senninger, N. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010;34:2442\u201351. https:\/\/doi.org\/10.1007\/s00268-010-0655-5.","DOI":"10.1007\/s00268-010-0655-5"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_003","doi-asserted-by":"crossref","unstructured":"Schuppan, D, Ashfaq-Khan, M, Yang, AT, Kim, YO. Liver fibrosis: direct antifibrotic agents and targeted therapies. Matrix Biol 2018;68\u201369:435\u201351. https:\/\/doi.org\/10.1016\/j.matbio.2018.04.006.","DOI":"10.1016\/j.matbio.2018.04.006"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_004","doi-asserted-by":"crossref","unstructured":"EASL. EASL recommendations on treatment of hepatitis C 2016. J\u00a0Hepatol 2017;66:153\u201394. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.001.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_005","doi-asserted-by":"crossref","unstructured":"Zeng, M-D, Lu, L-G, Mao, Y-M, Qiu, D-K, Li, J-Q, Wan, M-B, et al.. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005;42:1437\u201345. https:\/\/doi.org\/10.1002\/hep.20960.","DOI":"10.1002\/hep.20960"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_006","doi-asserted-by":"crossref","unstructured":"Sharma, S, Khalili, K, Nguyen, GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20:16820\u201330. https:\/\/doi.org\/10.3748\/wjg.v20.i45.16820.","DOI":"10.3748\/wjg.v20.i45.16820"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_007","doi-asserted-by":"crossref","unstructured":"Afdhal, NH, Nunes, D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:1160\u201374. https:\/\/doi.org\/10.1111\/j.1572-0241.2004.30110.x.","DOI":"10.1111\/j.1572-0241.2004.30110.x"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_008","doi-asserted-by":"crossref","unstructured":"Clerc, F, Reiding, KR, Jansen, BC, Kammeijer, GSM, Bondt, A, Wuhrer, M. Human plasma protein N-glycosylation. Glycoconj J 2016;33:309\u201343. https:\/\/doi.org\/10.1007\/s10719-015-9626-2.","DOI":"10.1007\/s10719-015-9626-2"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_009","doi-asserted-by":"crossref","unstructured":"Wang, M, Zhu, J, Lubman, DM, Gao, C. Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey. Clin Chem Lab Med 2019;57:407\u201316. https:\/\/doi.org\/10.1515\/cclm-2018-0379.","DOI":"10.1515\/cclm-2018-0379"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_010","doi-asserted-by":"crossref","unstructured":"Lin, Z, Simeone, DM, Anderson, MA, Brand, RE, Xie, X, Shedden, KA, et al.. Mass spectrometric assay for analysis of haptoglobin fucosylation in pancreatic cancer. J Proteome Res 2011;10:2602\u201311. https:\/\/doi.org\/10.1021\/pr200102h.","DOI":"10.1021\/pr200102h"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_011","doi-asserted-by":"crossref","unstructured":"Wang, M, Fang, M, Zhu, J, Feng, H, Warner, E, Yi, C, et al.. Serum N-glycans outperform CA19-9 in diagnosis of extrahepatic cholangiocarcinoma. Electrophoresis 2017;38:2749\u201356. https:\/\/doi.org\/10.1002\/elps.201700084.","DOI":"10.1002\/elps.201700084"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_012","doi-asserted-by":"crossref","unstructured":"Matsuda, A, Kuno, A, Nakagawa, T, Ikehara, Y, Irimura, T, Yamamoto, M, et al.. Lectin microarray-based sero-biomarker verification targeting aberrant O-linked glycosylation on mucin 1. Anal Chem 2015;87:7274\u201381. https:\/\/doi.org\/10.1021\/acs.analchem.5b01329.","DOI":"10.1021\/acs.analchem.5b01329"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_013","doi-asserted-by":"crossref","unstructured":"Callewaert, N, Van Vlierberghe, H, Van Hecke, A, Laroy, W, Delanghe, J, Contreras, R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429\u201334. https:\/\/doi.org\/10.1038\/nm1006.","DOI":"10.1038\/nm1006"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_014","doi-asserted-by":"crossref","unstructured":"Gui, H-l, Gao, C-f, Wang, H, Liu, X-e, Xie, Q, Dewaele, S, et al.. Altered serum N-glycomics in chronic hepatitis B patients. Liver Int 2010;30:259\u201367. https:\/\/doi.org\/10.1111\/j.1478-3231.2009.02170.x.","DOI":"10.1111\/j.1478-3231.2009.02170.x"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_015","doi-asserted-by":"crossref","unstructured":"Vanderschaeghe, D, Laroy, W, Sablon, E, Halfon, P, Van Hecke, A, Delanghe, J, et al.. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009;8:986\u201394. https:\/\/doi.org\/10.1074\/mcp.m800470-mcp200.","DOI":"10.1074\/mcp.M800470-MCP200"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_016","doi-asserted-by":"crossref","unstructured":"Fang, M, Zhao, Y-P, Zhou, F-G, Lu, L-G, Qi, P, Wang, H, et al.. N-glycan based models improve diagnostic efficacies in hepatitis B virus-related hepatocellular carcinoma. Int J Canc 2010;127:148\u201359. https:\/\/doi.org\/10.1002\/ijc.25030.","DOI":"10.1002\/ijc.25030"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_017","doi-asserted-by":"crossref","unstructured":"Yang, T, Xing, H, Wang, G, Wang, N, Liu, M, Yan, C, et al.. A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis B. Clin Chem 2019;65:1543\u201353. https:\/\/doi.org\/10.1373\/clinchem.2019.308965.","DOI":"10.1373\/clinchem.2019.308965"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_018","doi-asserted-by":"crossref","unstructured":"Scheuer, PJ. The nomenclature of chronic hepatitis: time for a change. J Hepatol 1995;22:112\u201314. https:\/\/doi.org\/10.1016\/0168-8278(95)80269-x.","DOI":"10.1016\/0168-8278(95)80269-X"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_019","doi-asserted-by":"crossref","unstructured":"Ho, C-H, Chien, R-N, Cheng, P-N, Liu, J-H, Liu, C-K, Su, C-S, et al.. Aberrant serum immunoglobulin G glycosylation in chronic hepatitis B is associated with histological liver damage and reversible by antiviral therapy. J Infect Dis 2015;211:115\u201324. https:\/\/doi.org\/10.1093\/infdis\/jiu388.","DOI":"10.1093\/infdis\/jiu388"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_020","doi-asserted-by":"crossref","unstructured":"Vallet-Pichard, A, Mallet, V, Nalpas, B, Verkarre, V, Nalpas, A, Dhalluin-Venier, V, et al.. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32\u20136. https:\/\/doi.org\/10.1002\/hep.21669.","DOI":"10.1002\/hep.21669"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_021","doi-asserted-by":"crossref","unstructured":"McPherson, S, Stewart, SF, Henderson, E, Burt, AD, Day, CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010;59:1265\u20139. https:\/\/doi.org\/10.1136\/gut.2010.216077.","DOI":"10.1136\/gut.2010.216077"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_022","doi-asserted-by":"crossref","unstructured":"Sterling, RK, Lissen, E, Clumeck, N, Sola, R, Correa, MC, Montaner, J, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 2006;43:1317\u201325. https:\/\/doi.org\/10.1002\/hep.21178.","DOI":"10.1002\/hep.21178"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_023","doi-asserted-by":"crossref","unstructured":"Zhao, Y-P, Ruan, C-P, Wang, H, Hu, Z-Q, Fang, M, Gu, X, et al.. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling. Cancer 2012;118:639\u201350. https:\/\/doi.org\/10.1002\/cncr.26342.","DOI":"10.1002\/cncr.26342"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_024","doi-asserted-by":"crossref","unstructured":"Fang, M, Dewaele, S, Zhao, Y-P, St\u00e4rkel, P, Vanhooren, V, Chen, Y-M, et al.. Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Canc 2010;9:215. https:\/\/doi.org\/10.1186\/1476-4598-9-215.","DOI":"10.1186\/1476-4598-9-215"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_025","unstructured":"Yang, XZ, Gen, AW, Xian, JC, Xiao, L. Diagnostic value of various noninvasive indexes in the diagnosis of chronic hepatic fibrosis. Eur Rev Med Pharmacol Sci 2018;22:479\u201385. https:\/\/doi.org\/10.26355\/eurrev_201801_14198."},{"key":"2021082201593411282_j_cclm-2020-1588_ref_026","doi-asserted-by":"crossref","unstructured":"Boursier, J, de Ledinghen, V, Leroy, V, Anty, R, Francque, S, Salmon, D, et al.. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol 2017;66:1158\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.003.","DOI":"10.1016\/j.jhep.2017.01.003"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_027","doi-asserted-by":"crossref","unstructured":"Haghgoo, SM, Sharafi, H, Alavian, SM. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review. Clin Chem Lab Med 2019;57:577\u2013610. https:\/\/doi.org\/10.1515\/cclm-2018-0357.","DOI":"10.1515\/cclm-2018-0357"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_028","doi-asserted-by":"crossref","unstructured":"Zou, X, Zhu, M-Y, Yu, D-M, Li, W, Zhang, D-H, Lu, F-J, et al.. Serum WFA-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection. Liver Int 2017;37:35\u201344. https:\/\/doi.org\/10.1111\/liv.13188.","DOI":"10.1111\/liv.13188"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_029","doi-asserted-by":"crossref","unstructured":"Morelle, W, Flahaut, C, Michalski, J-C, Louvet, A, Mathurin, P, Klein, A. Mass spectrometric approach for screening modifications of total serum N-glycome in human diseases: application to cirrhosis. Glycobiology 2006;16:281\u201393. https:\/\/doi.org\/10.1093\/glycob\/cwj067.","DOI":"10.1093\/glycob\/cwj067"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_030","doi-asserted-by":"crossref","unstructured":"Liu, X-E, Desmyter, L, Gao, C-F, Laroy, W, Dewaele, S, Vanhooren, V, et al.. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007;46:1426\u201335. https:\/\/doi.org\/10.1002\/hep.21855.","DOI":"10.1002\/hep.21855"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_031","doi-asserted-by":"crossref","unstructured":"Ishibashi, K, Nishikawa, A, Hayashi, N, Kasahara, A, Sato, N, Fujii, S, et al.. N-acetylglucosaminyltransferase III in human serum, and liver and hepatoma tissues: increased activity in liver cirrhosis and hepatoma patients. Clin Chim Acta 1989;185:325\u201332. https:\/\/doi.org\/10.1016\/0009-8981(89)90223-4.","DOI":"10.1016\/0009-8981(89)90223-4"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_032","doi-asserted-by":"crossref","unstructured":"Gressner, OA, Gao, C. Monitoring fibrogenic progression in the liver. Clin Chim Acta 2014;433:111\u201322. https:\/\/doi.org\/10.1016\/j.cca.2014.02.021.","DOI":"10.1016\/j.cca.2014.02.021"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_033","doi-asserted-by":"crossref","unstructured":"Friedman, SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247\u201350. https:\/\/doi.org\/10.1074\/jbc.275.4.2247.","DOI":"10.1074\/jbc.275.4.2247"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_034","doi-asserted-by":"crossref","unstructured":"Ismail, MH, Pinzani, M. Reversal of liver fibrosis. Saudi J Gastroenterol 2009;15:72\u20139. https:\/\/doi.org\/10.4103\/1319-3767.45072.","DOI":"10.4103\/1319-3767.45072"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_035","doi-asserted-by":"crossref","unstructured":"EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167\u201385. https:\/\/doi.org\/10.1016\/j.jhep.2012.02.010.","DOI":"10.1016\/j.jhep.2012.02.010"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_036","unstructured":"Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi (Chinese) 2019;27:938\u201361. https:\/\/doi.org\/10.3760\/cma.j.issn.1007-3418.2019.12.007."},{"key":"2021082201593411282_j_cclm-2020-1588_ref_037","doi-asserted-by":"crossref","unstructured":"Schiff, ER, Lee, SS, Chao, Y-C, Kew Yoon, S, Bessone, F, Wu, S-S, et al.. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011;9:274\u20136. https:\/\/doi.org\/10.1016\/j.cgh.2010.11.040.","DOI":"10.1016\/j.cgh.2010.11.040"},{"key":"2021082201593411282_j_cclm-2020-1588_ref_038","doi-asserted-by":"crossref","unstructured":"Lok, ASF, McMahon, BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661\u20132. https:\/\/doi.org\/10.1002\/hep.23190.","DOI":"10.1002\/hep.23190"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/cclm\/ahead-of-print\/article-10.1515-cclm-2020-1588\/article-10.1515-cclm-2020-1588.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-1588\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-1588\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T02:11:23Z","timestamp":1629598283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2020-1588\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2021,5,26]]}},"alternative-id":["10.1515\/cclm-2020-1588"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2020-1588","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"value":"1434-6621","type":"print"},{"value":"1437-4331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}